Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marcelo V. Negrao"'
Autor:
Waree Rinsurogkawong, John V. Heymach, Emily Roarty, Daniel R. Gomez, Lara Lacerda, Jianjun Zhang, Jadi M. Bohac, Jacqulyne P. Robichaux, Stephen G. Swisher, Vassiliki A. Papadimitrakopoulou, Melissa K. Shorter, Jack A. Roth, Jeff Lewis, Mara B. Antonoff, Hai T. Tran, Marcelo V. Negrao, Yasir Elamin, Xiuning Le
Publikováno v:
Clinical Lung Cancer. 20:43-47
Introduction Although most NSCLC patients with sensitizing epidermal growth factor receptor (EGFR) mutations have an impressive initial response, the vast majority has residual disease and develops acquired resistance after 9 to 14 months of EGFR tyr
Autor:
Xi Liu, John V. Heymach, Alissa Poteete, Matthias Pfeifer, Monique B. Nilsson, Jon Travers, Lixia Diao, Li Shen, Mia Hofstad, Hai T. Tran, Pan Tong, Jing Wang, Yuanxin Xi, Ethan Dmitrovsky, L. Hu, Youhong Fan, Xiuning Le, Ultan McDermott, Huiying Sun, Marcelo V. Negrao, Masanori Kawakami, David H. Peng, Jacqulyne P. Robichaux, Don L. Gibbons
Publikováno v:
Sci Transl Med
Acquired resistance to tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) remains a clinical challenge. Especially challenging are cases in which resistance emerges through EGFR-independent mechanisms, such as through pathwa
Autor:
Chun Ng, Caroline E. McCoach, Rebecca J. Nagy, Jacqulyne P. Robichaux, Young Kwang Chae, Victoria M. Raymond, Sai-Hong Ignatius Ou, Jeffrey M. Clarke, Funda Meric-Bernstam, Marcelo V. Negrao, Patrick Kwok Shing Ng, John V. Heymach, Viola W. Zhu, Monique B. Nilsson, Kimberly C. Banks, Emily Roarty, Junqin He, David R. Gandara, Trever G. Bivona, Richard B. Lanman, Bianca E. Amador, Jeffrey Crawford
Publikováno v:
J Thorac Oncol
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 15, iss 10
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 15, iss 10
IntroductionApproximately 4% of NSCLC harbor BRAF mutations, and approximately 50% of these are non-V600 mutations. Treatment of tumors harboring non-V600 mutations is challenging because of functional heterogeneity and lack of knowledge regarding th
Autor:
Franciele Hinterholz Knebel, Joao Victor Machado Alessi, Artur Katz, Anamaria A. Camargo, Luiz F. L. Reis, Manoel Cruz, Marcelo V. Negrao, Andrea K. Shimada, Fabiana Bettoni
Publikováno v:
Lung Cancer. 108:238-241
Osimertinib is an EGFR-T790M-specific TKI, which has demonstrated impressive response rates in NSCLC, after failure to first-line anti-EGFR TKIs. However, acquired resistance to osimertinib is also observed and the molecular mechanisms of resistance
Autor:
Gilberto de Castro, Marcos Tavares, Eduardo Furquim Simao, Marcelo V. Negrao, Ana O. Hoff, Luciana A. Castroneves, Alexander A. L. Jorge, Carla Papadia, Marco Aurélio Vamondes Kulcsar, Paulo M. Hoff, Julia Tizue Fukushima, Ricardo Miguel Costa de Freitas, José Viana Lima
Publikováno v:
Thyroid. 26:414-419
Treatment of advanced medullary thyroid carcinoma (MTC) was recently improved with the approval of vandetanib and cabozantinib. However, there is still a need to explore sequential therapy with more than one tyrosine kinase inhibitor (TKI) and to exp
Autor:
Garrett M. Frampton, Jordi Rodon Ahnert, Huiying Sun, Ting Chen, Lemei Hu, R. S. K. Vijayan, Zane Yang, John V. Heymach, Monique B. Nilsson, Kwok-Kin Wong, Funda Meric-Bernstam, Marcelo V. Negrao, Alexa B. Schrock, Brent Roeck, Junqin He, Cross Jason, Alissa Poteete, Richard B. Lanman, Xiuning Le, Jacqulyne P. Robichaux, Jing Wang, Fahao Zhang, Victoria M. Raymond, Mark J. Routbort, Shuai Li, Marlese Pisegna, Vincent A. Miller, Yasir Elamin, Lee A. Albacker, Lixia Diao, Han Han
Publikováno v:
Cancer Cell
We characterized the landscape and drug sensitivity of ERBB2 (HER2) mutations in cancers. In 11 datasets (n = 211,726), ERBB2 mutational hotspots varied across 25 tumor types. Common HER2 mutants yielded differential sensitivities to eleven EGFR/HER2
Autor:
Xiuning, Le, Sonam, Puri, Marcelo V, Negrao, Monique B, Nilsson, Jacqulyne, Robichaux, Theresa, Boyle, J Kevin, Hicks, Katherine L, Lovinger, Emily, Roarty, Waree, Rinsurongkawong, Ming, Tang, Huiying, Sun, Yasir, Elamin, Lara C, Lacerda, Jeff, Lewis, Jack A, Roth, Stephen G, Swisher, J Jack, Lee, William N, William, Bonnie S, Glisson, Jianjun, Zhang, Vassiliki A, Papadimitrakopoulou, Jhanelle E, Gray, John V, Heymach
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(24)
Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment ofUsing cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung